Nirmatrelvir + Placebo + Ritonavir
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-acute Sequelae of SARS-CoV-2 Infection
Conditions
Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID
Trial Timeline
Nov 8, 2022 → Sep 12, 2023
NCT ID
NCT05576662About Nirmatrelvir + Placebo + Ritonavir
Nirmatrelvir + Placebo + Ritonavir is a phase 2 stage product being developed by Pfizer for Post-acute Sequelae of SARS-CoV-2 Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT05576662. Target conditions include Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05576662 | Phase 2 | Completed |
Competing Products
1 competing product in Post-acute Sequelae of SARS-CoV-2 Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TNX-102 SL + Placebo SL Tablet | Tonix Pharmaceuticals | Phase 2 | 44 |